
Affidea Completes the Acquisition of MedEuropa Romania, and Opens a New Radiotherapy Centre in Iasi



The Hague, The Netherlands, May 21st, 2024: Affidea Group, the pan-European diagnostic imaging and community-based polyclinic and specialist healthcare provider, announced today that it has successfully completed the acquisition of MedEuropa Romania, a renowned cancer care provider.

This acquisition marks a significant advancement in Affidea's mission to enhance the continuum of cancer care for oncological patients throughout Romania.

In line with this commitment, Affidea is proud to announce the inauguration of a new state-of-the-art MedEuropa cancer care centre in Iasi, where Affidea is already well-established with a diagnostic imaging centre.



With a €15 million investment, the new centre is equipped with cutting-edge technology, including two Elekta linear accelerators (Linacs), designed to offer advanced radiotherapy treatments. One of the linacs is the new Versa HD, capable of precision stereotactic treatments with real-time respiratory monitoring, and the other one is Elekta Infinity, which supports sophisticated IMRT/VMAT and electron therapies. The new facility in Iasi will provide, besides radiotherapy, daily hospitalisation for oncology patients, as well as consultations for cancer treatment.



The facility is designed with three bunkers, with the third ready to house additional cutting-edge equipment in the upcoming months. The team includes 7 radiation oncologists, 5 medical physicists, and dedicated administrative staff, all committed to delivering superior patient outcomes. The new radiotherapy centre in Iasi will be officially launched at the end of the month.



Razvan Predica, Country CEO for Affidea Romania and Hungary, stated: "As we celebrate the completion of the MedEuropa acquisition and the opening of our new state-of-the-art cancer care centre in Iasi, we reinforce our commitment to combating cancer within our communities. This new step represents a significant stride towards closing the gap in oncology care by providing advanced diagnostics, laboratory analysis, radiotherapy and chemotherapy treatments with a wide range of complementary consultations under one network. We remain dedicated to improving survival rates and ensuring that every patient receives personalised and accessible care throughout their journey—from early detection to recovery."

Guy Blomfield, Group CEO and Chairman of the Management Board of Affidea, stated: "The successful acquisition of MedEuropa Romania and the opening of our new radiotherapy centre in Iasi add to our growing network, reaching today 362 centres across 15 countries in Europe. With this important milestone, we are further developing our portfolio of services in Romania, a key market in our network, and enhancing our ability to deliver timely, innovative cancer treatments, ensuring that every oncological patient benefits from the best possible care. By continually elevating our services, we aim to improve cancer survival rates and broader patient outcomes across all communities we serve."



With the completion of the MedEuropa acquisition and the addition of the new cancer care centre in Iasi, Affidea reaches 58 centres across Romania, adding radiotherapy services that perfectly complement the company's wide portfolio of advanced diagnostic services, multi-speciality consultations and laboratory analysis.

Affidea Group was advised by Rizoiu & Asociatii and Clifford Chance as legal advisors, while Deloitte served as financial advisor. The sellers were advised by Biris Goran and Linklaters as legal advisors.

Source & Image Credit: [Affidea](#)

Published on : Tue, 21 May 2024